Literature DB >> 27192377

Effects of Well-Controlled HIV Infection on Complement Activation and Function.

Alexandria E-B Rossheim1, Tina D Cunningham, Pamela S Hair, Tushar Shah, Kenji M Cunnion, Stephanie B Troy.   

Abstract

INTRODUCTION: Uncontrolled HIV infection is known to activate the complement system, leading to an increase in chronic inflammation. Whether or not this activation of complement persists and contributes to chronic inflammation in subjects with HIV infection that is well controlled through use of antiretroviral therapy has not been studied.
METHODS: We conducted an observational, cross-sectional study using sera from 305 adults with well-controlled HIV infection and 30 healthy controls. Sera was tested for markers of complement activation (C3a and C5a levels), complement function (CH50 assay), and immunoglobulin levels (IgG1-IgG4) as IgG can activate complement. We evaluated the association of well-controlled HIV infection with C3a, C5a, CH50, IgG1-IgG4, and total IgG levels using both univariate and multivariate analyses, controlling for factors such as age, sex, race, comorbidities (including hepatitis C coinfection), smoking status, and statin use.
RESULTS: Well-controlled HIV infection was associated with a 54% increase in complement activation as measured by C3a levels compared with healthy controls (P < 0.0001). Hepatitis C coinfection was associated with a further 52% increase in complement activation, as measured by C3a levels, over HIV alone (P = 0.003).
CONCLUSION: These results suggest that complement activation may contribute to a proinflammatory state even in well-controlled HIV infection. Furthermore, hepatitis C virus coinfection may be even more proinflammatory, in complement activation, compared with HIV infection alone.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27192377      PMCID: PMC4981513          DOI: 10.1097/QAI.0000000000001079

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  29 in total

Review 1.  Emerging role for complement in HIV infection.

Authors:  Georg Huber; Zoltán Bánki; Susanne Lengauer; Heribert Stoiber
Journal:  Curr Opin HIV AIDS       Date:  2011-09       Impact factor: 4.283

Review 2.  Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth.

Authors:  Liam G Coulthard; Trent M Woodruff
Journal:  J Immunol       Date:  2015-04-15       Impact factor: 5.422

3.  IgG subclass distribution in serum and various mucosal fluids of HIV type 1-infected subjects.

Authors:  M Raux; L Finkielsztejn; D Salmon-Céron; H Bouchez; J L Excler; E Dulioust; J M Grouin; D Sicard; C Blondeau
Journal:  AIDS Res Hum Retroviruses       Date:  2000-04-10       Impact factor: 2.205

4.  Complement activation is associated with the presence of specific human immunodeficiency virus (HIV)-anti-HIV immune complexes in patients with acquired immunodeficiency syndrome-related complex or lymphoadenopathy syndrome.

Authors:  C Carini; R Perricone; C Fratazzi; L Fontana; C De Carolis; R D'Amelio; M C Sirianni; F Aiuti
Journal:  Scand J Immunol       Date:  1989-09       Impact factor: 3.487

Review 5.  Residual immune dysregulation syndrome in treated HIV infection.

Authors:  Michael M Lederman; Nicholas T Funderburg; Rafick P Sekaly; Nichole R Klatt; Peter W Hunt
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

6.  Complement component C5a predicts future cardiovascular events in patients with advanced atherosclerosis.

Authors:  Walter S Speidl; Markus Exner; Jasmin Amighi; Stefan P Kastl; Gerlinde Zorn; Gerald Maurer; Oswald Wagner; Kurt Huber; Erich Minar; Johann Wojta; Martin Schillinger
Journal:  Eur Heart J       Date:  2005-05-25       Impact factor: 29.983

7.  Serum complements C3 and C4 in chronic HCV infection and their correlation with response to pegylated interferon and ribavirin treatment.

Authors:  Abd El-Fatah Fahmy Hanno; Khaled Mahmoud Mohiedeen; Akram Deghedy; Reeham Sayed
Journal:  Arab J Gastroenterol       Date:  2014-06-02       Impact factor: 2.076

8.  Rheumatoid factor expression and complement activation in children congenitally infected with human immunodeficiency virus.

Authors:  J N Jarvis; H Taylor; M Iobidze; J Dejonge; S Chang; F Cohen
Journal:  Clin Immunol Immunopathol       Date:  1993-04

9.  Evidence for activation of complement in patients with AIDS related complex (ARC) and/or lymphoadenopathy syndrome (LAS).

Authors:  R Perricone; L Fontana; C de Carolis; C Carini; M C Sirianni; F Aiuti
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

10.  Complement Effectors of Inflammation in Cystic Fibrosis Lung Fluid Correlate with Clinical Measures of Disease.

Authors:  Laura A Sass; Pamela S Hair; Amy M Perkins; Tushar A Shah; Neel K Krishna; Kenji M Cunnion
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

View more
  2 in total

1.  HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.

Authors:  Simone I Richardson; Amy W Chung; Harini Natarajan; Batsirai Mabvakure; Nonhlanhla N Mkhize; Nigel Garrett; Salim Abdool Karim; Penny L Moore; Margaret E Ackerman; Galit Alter; Lynn Morris
Journal:  PLoS Pathog       Date:  2018-04-09       Impact factor: 6.823

2.  Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination.

Authors:  Eunice W Nduati; Mathew J Gorman; Yiakon Sein; Tandile Hermanus; Dansu Yuan; Ian Oyaro; Daniel M Muema; Thumbi Ndung'u; Galit Alter; Penny L Moore
Journal:  AIDS       Date:  2021-10-01       Impact factor: 4.177

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.